Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion with a focus on a single resilient hair, jokingly called "chad hair," that remains despite hairline receding. Some users suggest microneedling and hair follicle cloning as potential treatments.

A user shared their positive experience with hair regrowth using finasteride and minoxidil, noting improvements in hair thickness and confidence. They also mentioned using a dermaroller and managing side effects, while others in the conversation shared similar experiences and advice on hair loss treatments.

A 33-year-old male shared his hair regrowth journey, using minoxidil, dermarolling, hair brushing, scalp oils, dietary changes, and supplements. After five months, he started finasteride to improve hair thickness.

A user shares their positive experience of embracing baldness, noting increased attractiveness and dating success after shaving their head. They encourage others to consider going bald instead of relying on medications like Minoxidil, finasteride, or RU58841.

Bimatoprost and latanoprost are being considered for scalp hair growth, with concerns about side effects like skin darkening and fat loss. A user warns about potential chemical burns from latanoprost.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

A 29-year-old is using liposomal topical finasteride/minoxidil and low-level light therapy (LLLT) to improve hair growth, showing significant progress in crown recovery. The user prefers liposomal topicals to avoid side effects from oral finasteride and uses the iRestore Essential device for LLLT.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

The conversation discusses "Hair bloom" hair filler, which contains biotin, collagen, and various peptides, as a potential alternative to PRP or mesotherapy for hair loss. Opinions vary, with some suggesting it may be a cash grab or ineffective, while others believe it could complement topical minoxidil for early hair loss.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

The user has been using finasteride, minoxidil, a dermastamp, and red light therapy for six months with no visible improvement since the three-month mark. Other users noted improvement, particularly in the left temple area, and encouraged the user to continue.

The conversation discusses using daily microneedling at 0.25mm and red light therapy to enhance hair regrowth, especially when traditional treatments like finasteride and minoxidil become less effective. The combination is said to improve hair density and thickness, with red light therapy being more cosmetic, while microneedling is essential for challenging areas.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

Dr. Bloxham's new channel will discuss verteporfin and other future hair loss treatments. Users express interest and hope for the effectiveness of these treatments.

People are excited about a new hair loss treatment, PP405, and some suggest using Twitter to increase its visibility. Current treatments mentioned include finasteride, minoxidil, and dutasteride, but skepticism remains about the effectiveness of new treatments.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

A user is considering exosome therapy from Springs Rejuvenation for hair loss after unsuccessful attempts with PRP, adipose injections, and a laser cap. They are intrigued by the therapy's potential and the clinic's guarantee of 30% improved coverage, despite concerns about FDA approval and high-pressure sales tactics.

The conversation is about a user experiencing positive hair regrowth results after using finasteride, minoxidil spray, dermapen, and low-level light therapy (LLLT) for four months. The user recommends using a specific device for LLLT and mentions using the Hims spray for finasteride and minoxidil.

Finasteride and minoxidil are recommended for hair loss, with skepticism about additional treatments like electro stimulation and oxygen infusion, which are seen as ineffective and costly. Pulsed ultrasound may enhance drug delivery, but most other treatments are considered ineffective.

A person struggling with hair loss is using treatments like dutasteride, oral minoxidil, and has had a hair transplant but remains deeply unhappy. Others suggest alternative treatments, acceptance, and focusing on other life aspects, emphasizing mental health and therapy.

DHT promotes beard growth but causes scalp hair loss due to inflammation and fibrosis. Treatments like finasteride and minoxidil help with hormonal signals and blood flow but don't address underlying inflammation.

Peptides like GHK-Cu, BPC-157, and TB-500 have significantly reduced hair loss, with GHK-Cu being particularly effective. The discussion also covers the high cost of these peptides and explores more affordable purchasing options.

A user is treating hair loss with 0.5mg Dutasteride three times a week, 5mg oral Minoxidil daily, and topical finasteride and minoxidil, seeing some improvement but insufficient density. They are considering increasing Dutasteride dosage and addressing high estradiol levels, while also trying to quit vaping.

A 35-year-old man had a hair transplant in 2019 but experienced further hair loss due to not using finasteride or minoxidil. Many suggest shaving his head or considering a hair system, as his donor area is depleted and further transplants may not be viable.

The user is frustrated with hair loss, having switched from topical minoxidil and finasteride to dutasteride and oral minoxidil without seeing improvements. They are considering a hair transplant and are advised to continue the current treatment and explore therapy or lifestyle changes.

Topical roflumilast is effective for reducing inflammation in various scalp conditions like seborrheic dermatitis, psoriasis, and eczema, but not proven to stop scarring alopecia. Alternatives like apremilast and Vtama are also discussed for their anti-inflammatory benefits.

A person dealing with hair loss is considering shaving their head, using scalp micropigmentation to cover a FUT scar, or trying a hair system. They are also contemplating treatments like minoxidil, finasteride, and dutasteride.